Drug Discovery in the p53 Pathway
1998

Drug Discovery in the p53 Pathway

publication

Author Information

Author(s): D.P. Lane

Primary Institution: University of Dundee

Hypothesis

The intrinsic resistance of many cancers to therapy may be due to loss of p53 function.

Conclusion

Understanding the control of the p53 pathway provides novel opportunities for drug discovery.

Supporting Evidence

  • Over 50% of human cancers have mutations in the p53 gene.
  • p53 becomes active as a transcription factor turning on the expression of genes that induce cell cycle block and promote apoptosis.
  • Interaction with the mdm2 protein is a key regulator of the p53 response.

Takeaway

Many cancers don't respond well to treatment because they have a broken p53 gene, which helps protect normal cells from damage.

Methodology

Peptides that block the p53 binding site on mdm2 were isolated and introduced into normal cells to activate the p53 response.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication